Rheoscience A/S, Rødovre 2610, Copenhagen, Denmark.
J Endocrinol. 2010 Sep;206(3):287-96. doi: 10.1677/JOE-10-0004. Epub 2010 May 27.
The availability of useful animal models reflecting the human obesity syndrome is crucial in the search for novel compounds for the pharmacological treatment of obesity. In the current study, we have performed an extensive characterization of the obesity syndrome in a polygenetic animal model, namely the selectively bred diet-induced obese (DIO) and diet-resistant (DR) rat strains. We show that they constitute useful models of the human obesity syndrome. DIO and DR rats were fed either a high-energy (HE) or a standard chow (Chow) diet from weaning to 9 months of age. Metabolic characterization including blood biochemistry and glucose homeostasis was examined at 2, 3, 6, and 9 months of age. Furthermore, in 6-month-old HE-fed DIO rats, the anti-obesity effects of liraglutide and sibutramine were examined in a 28-day study. Only HE-fed DIO rats developed visceral obesity, hyperleptinemia, hyperinsulinemia, and dyslipidemia, and showed a worsening of glucose tolerance over time. In line with the hyperlipidemic profile, a severe hepatic fat infiltration was observed in DIO rats at 6 months of age. The effects of liraglutide and sibutramine were tested in 6-month-old DIO rats. Both compounds effectively reduced food intake and body weight in DIO rats. Liraglutide furthermore improved glucose tolerance when compared with sibutramine. Our data highlights the usefulness of a polygenetic animal model for screening of compounds affecting food intake, body weight, and glucose homeostasis. Furthermore, the results underscore the effectiveness of GLP-1 mimetics both as anti-diabetes and anti-obesity agents.
有用的动物模型的可用性反映了人类肥胖症,这在寻找新型化合物治疗肥胖症方面至关重要。在目前的研究中,我们对多基因动物模型,即选择性饲养的饮食诱导肥胖(DIO)和饮食抵抗(DR)大鼠品系的肥胖症进行了广泛的特征描述。我们表明,它们是人类肥胖症的有用模型。DIO 和 DR 大鼠从断奶到 9 个月大时分别喂食高能(HE)或标准饲料(Chow)。在 2、3、6 和 9 个月大时检查代谢特征,包括血液生化和葡萄糖稳态。此外,在 6 个月大的 HE 喂养 DIO 大鼠中,在 28 天的研究中检查了利拉鲁肽和西布曲明的抗肥胖作用。只有 HE 喂养的 DIO 大鼠才会出现内脏肥胖、高瘦素血症、高胰岛素血症和血脂异常,并随着时间的推移出现葡萄糖耐量恶化。与高脂血症的特征一致,在 6 个月大时,DIO 大鼠出现严重的肝脂肪浸润。在 6 个月大的 DIO 大鼠中测试了利拉鲁肽和西布曲明的作用。两种化合物都有效地减少了 DIO 大鼠的食物摄入量和体重。与西布曲明相比,利拉鲁肽还改善了葡萄糖耐量。我们的数据强调了多基因动物模型在筛选影响食物摄入、体重和葡萄糖稳态的化合物方面的有用性。此外,结果强调了 GLP-1 类似物作为抗糖尿病和抗肥胖剂的有效性。